ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z

Abstract Number: 0567

Gain-of-Function Mutations in Lyn Kinase Cause a Novel Autoinflammatory Disease with Small Vessel Vasculitis and Liver Fibrosis
Abstract Number: 1784

Gait Alterations Associated with Worsening Physical Function over 2 Years: A Machine-learning Approach in the Multicenter Osteoarthritis (MOST) Study
Abstract Number: 1920

Gait and Physical Activity Predictors of Knee Replacement: A Machine Learning Analysis in the Multicenter Osteoarthritis Study
Abstract Number: 2159

Gastroesophageal Reflux Disease in an Australian Scleroderma Cohort – Associations and Effect of Treatment
Abstract Number: 1445

Gastrointestinal Manifestations in Systemic Lupus Erythematosus Are Associated with High Disease Activity and Mortality: A Nationwide Cohort Study from India
Abstract Number: 0882

Gender Differences in Rheumatology Authorship: A Bibliometric Analysis of High Impact Rheumatology Journals from 2019-2021
Abstract Number: 0111

Gender Equity in the Asia Pacific: Comparison of Indian and Philippines Rheumatology Conferences
Abstract Number: 0104

Gender Representation of the Editors and Editorial Boards of the Top 45 Rheumatology-Focused Journals
Abstract Number: 1219

Gender-Related Clinical Profile of Fibromyalgia Patients
Abstract Number: 1539

Gene Expression Meta-Analysis Reveals Aging and Cellular Senescence Signatures in Scleroderma-associated Interstitial Lung Disease
Abstract Number: 0361

Gene Expression Pathways Modulated by Anifrolumab in Systemic Lupus Erythematosus
Abstract Number: 0486

Gene Expression Profile of Temporal Artery Tissue and Whole Blood in Giant Cell Arteritis
Abstract Number: 2224

Genes Causative of Primary Immunodeficiency Are Risk Factors for and Over-expressed in Systemic Lupus Erythematosus
Abstract Number: 2250

Genetic and Environmental Risk Factors in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 1038

Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Ankylosing Spondylitis
Abstract Number: 1146

Genetic Interactions Between T-Cell Receptor Polymorphisms and HLA Amino Acids Contribute to the Risk of Rheumatoid Arthritis
Abstract Number: 1633

Genetic Risk, Adherence to a Healthy Lifestyle, and Incident Gout in US Women and Men
Abstract Number: 1940

Genetic Variants and Cytokine Signatures in Patients with Syndrome of Undifferentiated Recurrent Fevers
Abstract Number: 1892

Genicular Nerve Block for Pain Management in Patients with Knee Osteoarthritis: A Randomised Double-blind Placebo Controlled Trial
Abstract Number: 1134

Genome-wide Association Study Identifies Novel Loci for Leukopenia Among TPMT and NUDT15 Normal Metabolizers Taking Azathioprine
Abstract Number: 1621

Genome-wide Association Study in African American Systemic Sclerosis Patients Identifies a Novel Target – Transforming Growth Factor-β3 (TGFβ3)
Abstract Number: 1125

Genomics of JAK-STAT Signaling in Venous Thromboembolism
Abstract Number: 0072

Geographical Patterns of Healthcare Utilization Among RA and OA Patients
Abstract Number: 0489

Giant Cell Arteritis Phenotypes and Diagnosis of Aortitis Among 1852 Patients Before and After 2016 Across 10 French Referral Centers
Abstract Number: 0496

Giant Cell Arteritis Relapse Risk – Could the Extent of Vessel Involvement on Temporal and Axillary Arteries Ultrasound Be a Prognostic Marker?
Abstract Number: 0483

Giant Cell Arteritis: Physical Examination of the Superficial Temporal Arteries Can Predict Temporal Artery Biopsy Result
Abstract Number: 1078

Glucocorticoid Use and Related Adverse Events in ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis
Abstract Number: 0481

Glucocorticoid-related Adverse Events in Giant Cell Arteritis: Application of the Glucocorticoid Toxicity Index in a Monocentric Cohort of 140 Patients
Abstract Number: 1304

Glucocorticoids Affect Bone Mass and Strength by Inhibiting Osteoprogenitor Cell Maturation
Abstract Number: 0879

Golimumab for Treatment of Polyarticular Juvenile Idiopathic Arthritis – Safety and Effectiveness Updates from a Comparative Study
Abstract Number: 1789

Gout in Heart Failure Patients with Left Ventricular Assist Device Therapy in a Tertiary Academic Hospital
Abstract Number: 1733

Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium
Abstract Number: 1253

Gray Intensity Ratio Indices as a Method of Discrimination Between Changes Induced by Sport and by Spondyloarthritis in Load-bearing Entheses
Abstract Number: 2092

Greater Social Vulnerability Associates with Greater Glucocorticoid Use in Patients with SLE
Abstract Number: 0150

Growth and Differentiation Factor 15, an Emerging Biomarker of Mitochondrial Dysfunction- Associated Myopathies: Implications for Juvenile Dermatomyositis
Abstract Number: 2110

Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population
Abstract Number: 2127

Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years
Abstract Number: 1850

Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2
Abstract Number: 0509

Guselkumab Provides Sustained Improvements in Work Productivity and Daily Activity in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2
Abstract Number: 0507

Gut Microbe Metabolite Short-Chain Fatty Acids May Associate with Development of Respiratory Involvement in Patients with Relapsing Polychondritis
Abstract Number: 2181

Gut Microbe-derived Short-Chain Fatty Acids Regulate Arthritis and Myositis During Chikungunya Virus Infection
Abstract Number: 1148

GWAS Identified New Genes in Synovial Fibroblasts Linked to Early Remission in RA

Jump to: View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.